Luoxin Pharmaceutical (Shanghai) Co., Ltd.

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Medshine Discovery Inc.

Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

Shanghai Hansoh Biomedical Co., Ltd.

F. Hoffmann-La Roche Ag

Luoxin Pharmaceutical Co., Ltd.

Jiaqiang Dong

Shuhui Chen

Jian Li

Henner Knust

Andrew William Thomas

Bernd Buettelmann

Charles Z Ding

Bo Han

Lihong Hu

Tie-Lin Wang

Jianyu Lu

Huijun He

Shenyi Shi

Guoping Hu

Kevin X Chen

Weidong Li

Zhen Gong

Xu Zeng

Xiaobing Yan

Bin Shi

Fangfang Jin

Yuekun Nie

Jianglei Huang

Wenqian Yang

Wensheng Yu

Xinxian Deng

Zhijuan Chen

A nitrogen-containing heterocyclic derivative inhibitor, a preparation method therefor and the use thereof. Specifically disclosed are a compound as represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and the use thereof as an inhibitor in treating diseases such as cardiovascular and cerebrovascular diseases, wherein the definition of each substituent in the general formula (I) are the same as those defined in the description.

Nitrogen-containing heterocyclic derivative inhibitor, preparation method therefor and use thereof

Provided are a salt form of an estrogen receptor down-regulator, a crystalline form thereof, and a preparation method therefor

Salt form of estrogen receptor downregulator, crystalline form thereof, and preparation method therefor

Disclosed is a novel class of MDM2-p53 inhibitor compounds having an imidaxopyrolone structure, and specifically disclosed are compounds represented by formulas (I-1) and (I-2) and pharmaceutically acceptable salts thereof. 

Substituted pyrrolo[3,4-d]imidazoles as MDM2-p53 inhibitors

Disclosed are a crystal form of an estrogen receptor inhibitor and a preparation method therefor, in particular disclosed are a crystal form A of a compound of formula (I) and a preparation method therefor, and the use of the crystal form in the preparation of a drug for treating breast cancer. 

Crystal form of estrogen receptor inhibitor and preparation method therefor

Disclosed in the present invention is a type of indole substituted piperidine compounds as an estrogen receptor down-regulator. Specifically disclosed are a compound as shown in formula (I), a pharmaceutically acceptable salt, hydrate or prodrug thereof, a preparation method therefor, a pharmaceutical composition thereof, and a use thereof as an estrogen receptor down-regulator in the treatment of estrogen receptor positive breast cancers. 

Indolo substituted piperidine compound as estrogen receptor down-regulator

Disclosed is a new indole compound, in particular, the compound as shown in formula (I), and a preparation method, pharmaceutical composition and use thereof as an estrogen receptor down-regulator in preparing drugs for treating estrogen receptor-positive breast cancer. 

Substituted-indole-compounds as estrogen receptor down-regulators

Growing community of inventors

Shanghai, China

Jiaqiang Dong